MXPA01012650A - Delivery of a skin health benefit agent to a treated substrate for transfer to skin. - Google Patents

Abstract

The present invention relates to a combination for surface treatment of a substrate, e.g. a nonwoven web, used in personal care product applications. The surface treatment combination not only provides adequate fluid handling properties, but also provides a topical delivery system effective in depositing a thin, tenacious and substantially continuous coating of a skin health benefit agent on skin by an aqueous emulsion mediated dissolution of the agent from a substrate with subsequent transfer and deposition onto the skin. Coatings of the skin health benefit agent on the skin resist removal, thereby preventing damage to the natural skin barrier and providing a protective barrier against chemically- and biochemically-induced skin damage.

Description

DISTRIBUTION OF A BENEFICIAL AGENT FOR SKIN HEALTH A SUBSTRATE TREATED FOR TRANSFER TO THE SKIN FIELD OF THE INVENTION This invention is about the use of an age beneficial for the health of the skin to improve skin health. A combination of the treatment includes a surfactant agent beneficial to skin health that can be applied to a substrate such as a non-woven mesh, so that composition will impart adequate liquid handling properties to the substrate and will subsequently be transferred to the skin. the health of it. The composition of the treatment can also be used as a vehicle for distributing other agen to the skin, for example proteins.

BACKGROUND OF THE INVENTION The skin is by nature an excellent protection against the penetration of many foreign substances. From time to time, the skin's natural ability to provide protection is compromised by external factors including abrasions, irritations and the like. In recent years they have made efforts to promote the health of the skin through the use of various products that contain additives developing synthetic or natural polymers that mimic complement the properties of the skin in order to maintain the health of it.

Several agents are known that improve the properties of the skin when applied to it and to hair. Although the effective distribution of beneficial skin health agents that can improve preventing damage to the underlying protective barrier of the skin is not yet known.

Improving the health of the skin and distributing agent to the skin to promote skin health has many advantages including: 1) protect the skin and keep it in a moist condition, essentially free of cracks or irritation, 2 regulate the pH and strengthen the barrier to maintain or improve the base properties of the skin, 3) inhibition of irritants that are suspected to promote irritant dermatitis or allergic contact, and 4) maintain the lubricity of the skin.

The permeability of the skin for a foreign substance is influenced by a combination of physical chemical parameters for both the target and the vehicle, if applicable, which delivers the objective. Keeping the skin healthy its underlying protective properties requires optimal physical and chemical properties of the skin.

U.S. Patent No. 4,556,560 par Buckingham, assigned to Procter & Gamble Company, discloses method for treatment and prophylaxis of diaper rash and dermatitis using a lipase inhibiting agent in the water-soluble metal salt form, such as ZnCl 2.

There is a need for a composition of treatment for use with a Substrate which is capable of distributing a thin, adhesive, substantially continuous film of beneficial agent for the health of the skin to the skin which can avoid reducing skin irritation, maintaining the pH and maintain the hydration and lubrication of the skin. The combination of the present invention satisfies this need. In addition, although bene? Cial skin additives are known, other compositions have had undesirable side effects that reduce moisture the rate of liquid admission of the Substrate. There is still a need for a combination of treatment for application and use with a Substrate which does not adversely affect the liquid handling properties of the Substrate, for example the speed of rapid and continuous liquid intake.

SUMMARY OF THE INVENTION The present invention relates to a combination for surface treatment of a Substrate, for example a non-woven mesh, used in personal care products applications. The combination of non-sol surface treatment provides adequate liquid handling properties, without also providing an effective topical distribution system for placing a thin, adhesive and substantially continuous coating of a beneficial agent for the health of the skin on the skin by means of of a mediated dissolution of an aqueous emulsion of the agent from a substrate with transfer and subsequent placement on the skin. Coatings of beneficial agent for skin health on the skin resist removal, by itself they avoid the damages to the natural protective barrier of the foot and providing a protective barrier against mechanical chemical damage, and biochemically induced to the skin. It also provides a combination of treatment for application with a Substrate that will not adversely affect the liquid properties of the Substrate, for example the continuous rapid rate of liquid intake whenever the material / product is used.

BRIEF DESCRPTION OF THE DRAWINGS The presentation of this Patent contains at least one drawing that is shown in color. Copies of this Patent with color drawings will be provided by the Patent Office and trademarks upon request and payment of the necessary fee.

FIG. 1 is a schematic illustration of a treatment process useful in applying the treatment combination of the present invention to one or both sides of the non-woven mesh.

FIG. 2 is a vertical plane view partly in section of an example of the personal care product, in this case a diaper, which may be used by the treatable Substrat according to the present invention.

FIG. 3 is a 200X optical microscopy (d Bright Field and Fluorescent Image) of a Substrate treated with a treatment composition according to an aspect of the present invention.

FIG. 4 is a 200X optical microscopy (d Fluorescent Image) showing the mediated transfer of liquid from the treatment composition of the treated Substrate that dissolves in the liquid.

FIG. 5 is an optical microscopy of 200 (Fluorescent image) of the skin that has been treated with a treatment composition that includes mediated transfer of liquid from the composition to the skin, wherein the beneficial agent for skin health has been marked with a fluorescent tint to show the transfer of a thin, adhesive film, substantially continuous to the skin.

FIG. 6 is a 100X optical microscopy (Brilliant Camp and Fluorescent Image) of the skin that has received treatment according to the prior art wherein the treatment composition was transferred to the skin mediated by mechanical transfer, wherein a silk protein was marked with a fluorescent dye to demonstrate the transfer of a substantially discontinuous film to the skin.

FIG. 7 is a graph comparing the inhibition of proteolytic activity by zinc sulfat heptahydrate according to the present invention.

FIG. 8 is another graph comparing the inhibition of proteolytic activity by zinc heptahydrate d sulfate according to the present invention.

FIG. 9 is a graph showing the reduction of interleukin-1 alpha released by zinc according to the present invention.

FIG. 10 is a graph showing the reduction of interleukin-1 alpha released by zinc according to the present invention.

DETAILED DESCRIPTION OF THE INVENTION By means of the present invention combinations and methods are provided for topical composition administration of the treatment for the skin of mammals, especially humans to protect the skin by the preservation and restoration of the natural integrity thereof. This is achieved by placing a beneficial agent for the health of the skin of a substrate that is able to control the release of the agent to the surface of the skin and that is able to provide adequate handling of the body fluids. The beneficial agent for the health of the foot acts as a protector that is able to maintain the pH of the skin, inhibit the activity of irritants to the skin and maintain the hydration and lubrication of the skin. Pancreatic digestive enzymes that are eliminated by the body with feces have been linked to skin inflammation (Anderson, pH Bucher, AP, Saes, II, Lee, PC, Davis, JA, and Maibach, HI Fecal Enzymes: irritation of skin in vivo Dermatitis d Contact 1994; 30, 152-158). When feces, which include these enzymes, come in contact with the skin, the skin becomes irritated. In some cases, proteases, faeces and urine penetrate the stratum corneum proteins that can cause disintegration of the natural protective barrier of the skin. The skin is now susceptible to irritation by these molecules as well as other components in the stool and urine. The treatment composition of the present invention is designed to form a thin, adhesive film, substantially continuous on the skin to inhibit, or at least minimize, the effect of said irritants.

The treatment composition of the present invention includes a surfactant system and a beneficial agent for skin health. Preferably, the composition of the treatment is prepared as an emulsion of the surfactant and as a beneficial agent for the health of the skin, usually as an oil-in-water emulsion.

Examples of emulsions including aqueous emulsification of beneficial agent for the health of the skin, for example zinc sulphate heptahydrate, and surfactant, for example AHCOVEL Base N-62 (hereinafter "AHCOVEL"), a monoleate d-blend of sorbitan and hydrogenated polyethoxylated hydrogenated oil manufactured by Hodgson Company. It has been found that when using emulsions containing about 75 by weight of surfactant and up to about 25% by weight of beneficial agent for skin health in about 0.40% by weight of total solids, sufficient amounts of beneficial agent for the health of the skin are transferred to the skin. Preferably, the emulsions will contain from about 5 to 30% by weight of solids. These emulsions can be applied to the stratum from a bath with a large proportion of solids (up to 40% by weight) or dilution bath ranging from 0.1% by weight to approximately 20% by weight. Preferably, the emulsion will be diluted to about 0.5% by weight to about 15% by weight.

The surfactants useful in the treatment composition of the present invention will provide superior performance of fluid handling, skin protection and softening to human skin. Useful examples of surfactant include fatty acid and ethoxylated alcohols, monosaccharides, monosaccharide derivatives, polysaccharides, polysaccharide derivatives, combinations thereof.

Hydromiscible anionic surfactants are preferred and commercially available. Examples of these surfactants include AHCOVEL and Glucopon 220UP, available from Henkel Corporation, which is an alkyl polyglycoside having 8 to 10 carbons in the alkyl chain, and which can be used as part of the surfactant. Other well-known anionic surfactants are the aliphatic alcohol ethoxylates, the secondary ethoxylates of aliphatic alcohol, alkylphenol ethoxylates and the condensates of primary ethylene oxide propylene oxide in alkanole, such as PLURAFACS and PLURONICS (available from BASF Inc.) and oxide condensates. ethylene with sorbitan fatty acid esters such as the TWEEN series (also available from Uniqema). The anionic surfactants are generally the condensation products of an organic aliphatic compound and a hydrophobic aromatic alkyl compound and hydrophilic group of ethylene oxide. Virtually any hydrophobic compound having a carboxy, hydroxy, amido amino group with a free hydrogen bound to nitrogen can be condensed with the ethylene oxide or with the polyhydration product thereof, polyethylene glycol, to form a hydromiscible anionic surfactant. Other suitable surfactants include poly (oxyethylene) sorbitan monolaurate, poly (oxyethylene) sorbitan monostearate, poly (oxyethylene) sorbitan trioleate, poly (oxyethylene) sorbitan sorbate, and bovine lipid extract surfactant (Survanta, Ros Laboratories), a drug used for treat the Severe Respiratory Fatigue Syndrome and Cystic Fibrosis, and enzymes such as papain or pepsin that penetrate protein structures.

More specifically the anionic surfactant can include the condensation products of a higher alcohol (eg, an alkanol containing about 8, 9, 10 11, 12, 13, 14, 15, 16, 17 or 18 carbon atoms in a straight or branched chain configuration) condensed with about 5 to 30 moles of ethylene oxide. Examples include: lauryl or myristyl alcohol condensed with about 16 moles of ethylene oxide (EO); tridecano condensed with approximately 6 moles of EO; myristyl alcohol condensed with approximately 10 moles of EO per mo of myristyl alcohol; the condensation product of EO with a cut of coconut fatty alcohol contains a mixture of fatty alcohols with alkyl chains varying from 10, 11, 12, 13 or 1 carbon atoms in length and where the condensate contains either 6 moles of EO per mole of the total alcohol approximately 9 moles of EO per mole of alcohol; and ethoxylated tallow alcohol containing 6 EO to 11 EO per mole of alcohol Condensates of 2 to 30 moles of ethylene oxide with mono acid esters and 3C10 _ C20 sorbitan alkanoics having an HL (hydrophilic-lipophilic balance) of about 4 to 20, preferably about 8 to 15, which can also be used as anionic surfactant.

Another class of surfactant compounds includes alkyl polysaccharides. Alkyl polysaccharides or alkyl polyglycosides having the formula SUGAR-O-R, where R is a hydrophobic group.

Returning to the beneficial agent for skin health, the present invention provides zin compositions for reducing or preventing skin irritation and / or severe inflammatory skin reactions. Examples of said agent include zinc salt, zinc sulfate monohydrate, the like. Fortunately the zinc salt will be present in the composition as an aqueous emulsion. These agents are useful as astringents and enzyme inhibitors, and more particularly they are useful for inhibiting both fecal and urinary proteases. Zinc may interact directly with the catalytic site of the protease, in particular, the class of proteases known as serine proteases, to inhibit proteolytic activity. By inhibiting the proteolytic activity, the intention is to keep the skin without irritation, the place to give the treatment once it is already irritated. An advantage of the beneficial agent for the health of the skin, of the present invention is related to the reduction of the pH. The proteases d serine, for example, trypsin and pancreatic elastase, which are present, for example, in the faeces and urine have a pH of about 8.0 and 8.5 respectively. It has been unexpectedly discovered that the beneficial agent for the health of the The skin of the present invention reduces the pH thereby reducing the catalytic efficiency of these proteases.

The amount of beneficial agent for the health of the skin will be introduced in the combination described above on the scale of about 0.01% about 10% by weight of the composition. Preferably the agent will be present in the amount of about 0.25% to about 1% by weight of the composition.

Also provided in the present invention are compositions and methods for topical administration of the beneficial agent for skin health concurrently with a protein that can be administered topically in a controlled manner.

This protein is sericin. Sericin is one of the two proteins that are part of the double fibroin silk thread woven by Bombyx mori, a domestic insect. The sericin acts as a wrap around the fibroin thread. It is tissue, which is like spinning fibers with soluble sizing agents to help form good quality fibers. L sericin can be easily separated from the thirst protein by hydrolysis. The sericin additionally woven with its unique properties, is known to have great affinity to a number of proteins. When it is refined to a substance of great molecular weight it is easy to gather the keratin of the skin and hair forming a resistant film that moisturizes and protects the skin / hair, which imparts good protective properties.

Sericin is a wax protein that is obtained by controlled hydrolysis of silk with low molecular weight having a specific gravity of at least about 1. A commercially available silk protein is obtained from Croda, Inc., of Parsippany, NJ, and it is sold under the commercial name of CROSILK LIQUID (silk amino acid), CROSILK 10.00 (hydrolyzed silk), CROSILK POWDER (powdered silk), and CROSILKQUA (hydroxypropyl hydroxypropyl silk amino acid). Another example of a commercially available silk protein e SERICIN, which can be obtained from Pentafarm, LTD, a division of Kordia, bv, in the Netherlands. Additional details of said silk protein blends can be found in U.S. Patent No. 4,906,460, to Kim, et al., Assigned to Sorenco, which is incorporated herein by reference in its entirety.

Silk protein derivatives can be chosen from a variety of potential compositions. Included among silk derivatives are silk fibers and hydrolyzed silk fibers. The silk fibers can be used in the form of powder in the preparation of emulsion or as a powder of a product obtained by washing and treating silk fibers with an acid. Preferably, the thirst fibers are used as a product obtained by hydrolysis with an alkali acid or enzyme as disclosed in U.S. Patent Number 4,839,168 to Abe et al.; U.S. Patent Number 5,009,813 to Watanube et al., And U.S. Patent No. 5,069,898 to Goldberg, each incorporated herein by reference in its entirety.

Another silk derivative which can be employed in the composition of the present invention is the protein obtained by degumming natural silk as disclosed, for example in U.S. Patent No. 4,839,165 to Hope et al. , which is incorporated herein by reference in its entirety. The main protein obtained from natural silk is sericin, which has an empirical formula of C15h2503N5 and a molecular weight of approximately 323.5.

A preferred silk derivative is a mixture of two or more individual amino acids that are natural silk. The main silk amino acids are glycine, alanine, serine and tyrosine.

Another example of a silk derivative for use in the composition of the emulsion of the present invention is a fine powder of silk fibroin in non-fibrous or particulate form as disclosed in U.S. Patent No. 4,233,212 to Otoi et al. ., which is incorporated herein by reference in its entirety.

The fine powder is produced by dissolving a de-gummed silk material in at least one solvent selected from, for example, an aqueous solution of cuprietylene diamine, a solution of aqueous ammonia of copper hydroxide, an aqueous alkaline solution of copper hydroxide and glycerol , a solution of aqueous lithium bromide, an aqueous solution of calcium, magnesium or zinc chloride, nitrate or thiocyanate and an aqueous solution of sodium thiocyanate. The resulting fibroin solution is then dialyzed. The dialyzed aqueous silk fibroin solution having a silk fibroin concentration of from about 3 to 20% by weight, is subjected to at least one treatment for coagulation and precipitation of silk fibroin, such as, for example, the addition of a coagulant sa, by ventilation, by coagulation in the isoelectric point, by exposure to ultrasonic waves, by agitation at high cutting speed and the like.

The resulting product is a silk fibroin gel, which can be incorporated directly into the treatment composition or it can be dehydrated and dried in a powder and then dissolved in the treatment composition.

The silk material used to form the silk fibroin includes cocoons, raw silk, waste buds, raw silk waste, and similar silk fabric waste. The silk material is degummed or freed from lysine by a conventional procedure such as, for example, washing in hot water containing an active agent or surfactant or an enzyme, and then drying. The gum-free material is dissolved in the solvent and preliminarily heated to a temperature of from about 60 to 90 ° C, preferably from about 70 to 85 ° C. Additional details of the process for obtaining silk fibroin are discussed in the aforementioned Patent No. 4,233,212 of the United States.

In addition to the silk protein of the treatment composition of the present invention, an additional protein may be present in the amount of about 0.1 about 4.0% by weight. This additional protein may be selected from the group consisting of collagen hydrolyzed anima protein which is obtained by an enzymatic hydrolysis of lexine protein, vegetable protein and hydrolyzed trig protein and mixtures thereof.

The composition of the present invention may take the form of an oil-in-water emulsion or after dilution with water, with essential ingredients such as water-surfactant, and / or co-surfactant.

Because the composition that is prepared is an aqueous liquid formula and as no particular mixture is required to form the oil-in-water emulsion, the composition is easy to prepare since only all the ingredients in a container or mixture are combined. suitable container. The order of mixing the ingredients has no particular importance and generally the various ingredients can be added sequentially or all at once in the form of aqueous emulsions of each or all of the primary surfactants and co-surfactants can be prepared separately and combined. among them. It is important to note that the emulsions ofFor example, organic acid emulsions would not be acceptable for use in the present invention, since such emulsions are a strong irritant to the skin and would be counterproductive to the use of the present invention. The protein, when present, can be added as an aqueous emulsion of the same can be added directly. It is not necessary to use high temperatures in the formation step and the ambient temperature is sufficient. However, higher temperatures of up to about 180 ° F (82.2 ° C) preferably 110 to 140 ° F (43.3 to 60 ° C) can also be used.

For administration to the skin of a human or other mammal, the treatment compositions are often sterilized or formulated to contain one or more preservatives for incorporation into cosmetic or veterinary pharmaceutical formulations. These treatment compositions can be sterilized by conventional well-known sterilization techniques, for example, boiling pasteurization / without substantially and adversely affecting the logical activity of the composition. The compositions may contain pharmaceutically acceptable auxiliary substances as required to achieve physiological conditions and as necessary to prepare convenient administration compositions, such as pH adjusting and compensating agents, preservatives and distribution vehicles. Reactive methods for making pharmaceutically administrable compounds will be known or apparent to those skilled in the art and are described in detail for example in Remington's Pharmaceutica Science, supra.

In the present invention it is also possible to incorporate perfumes, dyes and pigments into the treatment compositions. For semi-solid compositions, as can be seen in the topical administration creams and pastes, they can provide peptone and copper complexes separately and can be mixed with conventional non-toxic carriers such as, for example, aloe vera gel, squalene, stearate glycerol, polyethylene glycol glycol, cetyl alcohol, stearic acid, propylene glycol, among others. Said compositions may contain approximately 5 to 100% active ingredients, better still approximately 5-25%.

Compositions formulated for administration to the skin are administered to a user, such as a human, with a healthy skin or in situations where a subject already suffers from skin damage (e.g. skinning) due to ultraviolet ray or other irradiation or damage In the skin by oxidation The treatment compositions are administered in a sufficient amount that allows inhibition or further damage by means of topically administered irritant substances or other known irritant substances and are more effective than if the host did not receive treatment. The adequate amounts to satisfy these effects are defined as "therapeutically effective dose" and will vary according to the application.

In prophylactic and cosmetic applications the compositions are used to protect the skin from injuries. In this way the beneficial agents for skin health and / or skin proteins are administered to a host under conditions that protect the integrity of the skin, maintain the physiological p, hydration and lubricity of the skin. In these uses, the precise amounts depend again on the amount of protection desired and on the extent and conditions under which the skin is exposed to potentially harmful conditions such as those caused by urine faecal proteases, or other irritating substances. These can generally range from about 0.1 mg to about 10 m per day per square centimeter of skin. Single or multiple administrations of the compositions may be carried out daily or over a prolonged period of time.

The silk proteins of the invention can be administered to the skin in relatively large amounts if serious secondary damage, although indiscriminate use can produce skin irritation. In cases where the compositions are administered prophylactically to inhibit oxidation or biochemical damage to the skin or those that suffer only from light dermatological damage, irritation and inflammation of the skin, the dose should be adjusted to lower maintenance levels.

The treatment composition provides skin protection and improves repair of the present invention, including pharmaceutical compositions, which can be administered alone or as a combination or in combination with prophylaxis or therapy. For example, the treatment compositions can be used in combination with other skin protection factors or those found to improve other protection or healing aspects. In this way, a synergistic effect can be obtained that produces a clinical efficacy greater than that made with any single factor.

In addition, although the compositions described herein stimulate a spectrum of processes for skin protection, the skin can differ considerably in its properties, and lead to the use of a combination of a composition described herein and another factor compound.

Factors with reported curative properties that may be included with thirst protein compositions for use in protection / cure formulas and methods of the present invention include, for example, epidermal growth factor, fibroblast growth factor. nerves, transformation growth factors, angiogenic growth factors, fibronectin heparin, fibrin, platelet derived growth factor, enzymatic superoxide dismutase, blood extracts or other factors of the blood factors.

Substrates particularly adapted to receive bodily elimination fluids such as menses, mucus, blood products, other feces, which will be apparent to those skilled in the art, are useful in the present invention. As used herein, the term "substrate" refers to a material that can be a woven fabric, knitted fabric, non-woven mesh, foam, material with a film appearance (for example, a film-like material with openings) or paper material. In particular, useful substrates include infant care products and children such as disposable diapers, training pants baby wipes, feminine hygiene products such as devices, menstruation absorbers such as sanitary napkins and tampons, for example bandages and incontinence products. . According to the invention the Substrate is usually hydrophobic and contains a treatment composition placed so as to make contact with the exudate. Many polymers useful in the formation of non-woven meshes, for example polypropylene, are hydrophobic and highly polar. Therefore, there is no affinity between the substrate and silk protein, making the application of silk protein to substrate difficult. The unique combination of the silk protein with the surfactants of the present invention overcomes this lack of affinity. In other words, the surfactant serves as a means to transport the silk protein for application to the Substrate. As is known to those skilled in the art, some synthetic fibers such as nylon are hydrophilic, and therefore will not have this particular problem with respect to to the present invention Fortunately, the substrate is a non-woven mesh, for example, a woven, molded, shaped carded agglomerated mesh. Additional substrates that may be used include foams and films that are fibrillated, apertured or otherwise treated to obtain fiber-like properties as well as sheets of these and / or non-woven meshes. Depending on the particular application, the substrate may be used. as liner in contact with the body, a distribution layer between a liner layer and an absorbent layer, an absorbent layer or in more than one of these layers.

As used herein, the term "non-woven mesh fabric" means a mesh having a structure of individual fibers or threads, which are interlaced, but which is not regularly identified as a woven fabric. The term also includes filaments and individual threads, stamens, towings, or foams or films that have been fibrillated open, or otherwise treated to impart fabric-like property. The non-woven fabrics or meshes have been formed from many processes such as, for example, blow-molding processes, weaving processes, forming processes, agglomerated carded mesh processes. The basis weight of the non-woven mesh is usually expressed in ounces of square material (osy) or grams per square meter (gsm) and the useful fiber diameters are usually expressed in microns (Note that to convert osy a gsm, multiply osy po 33.91).

As used herein, the term "microfibers" means fibers of small diameter having an average diameter of no more than about 50 microns, eg, average diameter of from about 5 microns to about 50 microns, or more particularly, microfibers which they can have an average diameter from about 2 miera to about 40 micras. Another frequently used fiber diameter expression is denier, which is defined as grams per 9000 meters of a fiber that can be calculated as fiber diameter in square microns, multiplied by the density in gram / ce, multiplied by 0.00707. A lower denier indicates a very fine fiber and a high denier indicates a thick or heavy fiber For example, the diameter of a polypropylene fiber determined as 15 microns can be converted to denier by squaring it, multiplying the result by 0.89 g / cc by multiplying by 0.00707. Thus, a polypropylene fiber of 15 microns has a denier of approximately 1.42 (152 x 0.89 x 0.00707 = 1.415). Outside the United States, the most common measurement unit is "tex", which is defined as grams per kilometer of fiber. The tex can be calculated com denier / 9.

As used herein the term "spun fiber" refers to small diameter fibers that are formed by extrusion of molten thermoplastic material with filaments from a plurality of thin, usually circular, single filament capillaries with the diameter of the extruded filaments. which are then rapidly reduced as an example is described in U.S. Patent No. 4,340.56 to Appel et al. , and U.S. Patent No. 3,692.61 to Dorschner et al., U.S. Patent No. 3,802.81 to Matzuki et al., U.S. Patent No. 3, 338, 992, 3,341,394 to Kinney, U.S. Pat. United States No.3,502.76 for Hartmann, U.S. Patent No. 3,502,538 for Lev and U.S. Patent Number 3,542,615 for Dobo et al Spun fibers are tempered and usually not tacky when deposited on the picking surface and generally subject to an independent step of union. The spun fibers are generally continuous and have average diameters that are frequently greater than 7 microns, more particularly between approximately 10 and 20 microns.

As used herein the term "molten fiber" means fibers that are formed by extrusion of molten thermoplastic material through a plurality of generally circular or fine capillaries, such as yarn or filaments fused at high converging velocity, generally heated, with gas streams (e.g. air) that attenuate the filaments of the molten thermoplastic material to reduce s diameter, which may be to a microfiber diameter. Then, the molten fibers are transported by the gas velocity stream and are deposited on a collection surface generally while still being viscous to form a mall of randomly dispersed fused fibers. Said process is disclosed, for example, in United States Patent No. 3, 849.24 to Butin. The melted fibers are microfibers which are generally continuous, but which can also be discontinuous and are generally smaller than the average diameter of 1 microns.

The substrate of the present invention may also include an agglomerated carded mesh. As used herein, "agglomerated carded meshes" or "MCA" refers to the non-woven meshes that are formed by cardadur processes as are known to those skilled in the art and which are described below, for example, in FIG. U.S. Patent No. 4,488,928 Concession for Alikhan and Schmidt which is hereby incorporated by reference in its entirety. Briefly, the carder processes include starting with a blend of eg staple fibers with binding fibers or other binder components in a block of fibrous or bulky material that is brushed or otherwise treated to provide a generally uniform weight. This mesh is heated or otherwise treated to activate the adhesive component which resulted in a generally excellent nonwoven integrated material.As can be understood by any person skilled in the art, said protected meshes can be formed of different types of polymers, which can be excluded as filaments of component fibers, biconstituent fibers and / or conjugated fibers (multi and bicomponent fibers). The biconstituent fibers are also sometimes called multi-constituent fibers. Fibers of this general type are discussed in, for example, U.S. Patent No. 5, 108, 827 to Gessner. Bicomponent and biconstituent fibers are also discussed in the Manua Mixtures and Polymer Compounds by John A. Manson and Leslie H Sperling copyright 1976 by Plenum Press, a division of the Publishing Corporation of New York, IBSN 0-306-30831-2, in pages 273 to 277. The conjugate fibers are disclosed in U.S. Patent No. 5,108,820 to Kaneko et al., U.S. Patent No. 5, 336, 552 to Strack et al., U.S. Patent No. 5,382,400 for Pike et al.

Small amounts of additive can be added to give color, antistatic properties, lubricity hydrophilicity, antibacterial, anti-mold, deodorizing effect and the like. These additives, for example titanium dioxide which is added to color and chitosan as an antibacterial, are generally present in an amount of less than 5% by weight more typically in about 2% by weight.

As used herein, the term "personal care product" includes diapers, calzone trainers, swimming pants, absorbent calzone, incontinence products for adults, sanitary napkins, feminine sanitary products such as sanitary napkins, tampons, gauze and bandages for wounds.

As used herein, the term "hydrophilic" means that the polymeric material has a friction-free surface such that the polymeric material is wettable by an aqueous medium, that is, a liquid medium of which the agu is the main component. The term "hydrophobic" includes materials that are not hydrophilic according to the definition, hydrophobic materials can be treated internally or externally with surfactants and the like to present them in a hydrophilic manner.

The substrate of the present invention can be a multilayer sheet. An example of a multilayer laminate is an embodiment wherein some of the layers are woven and some are fused such as the woven / fused / woven laminate (SMS) which is disclosed in U.S. Patent No. 4,041, 203 for Brock et al., U.S. Patent No. 5,169,706 to Collier, et al., and U.S. Patent No. 4,374,888 to Bornslaeger. Said substrates generally have a basis weight of about 0.1 to 12 osy (6 400 gsm), or more particularly about 0.75 about 3 osy.

Non-woven spunbond fabrics are usually bonded in some way in which they are processed in order to provide them with sufficient structural integrity to withstand the rigors of further processing of a finished product. The connection can be carried out in various ways such as hydro-wiring, puncture, ultrasonic bonding, adhesive bonding with stitches, connection through air and thermal bonding as calendering.

The addition of the treatment composition to substrate can be carried out by conventional means such as spraying, coating, dipping, and the like, although the use of the spray of large amounts of subtle and solid substances in cases where it is desired to minimize drying and / ol compression. The amount of treatment composition that is used will depend on the particular end use as well as the factors such as the base weight and the porosity of the substrate. Referring to FIG 1, the process shows, it will be defined for application to one or both sides of a movable Substrate. Those skilled in the art will appreciate that the invention is equally applicable to either on-line treatment or a separate treatment step outside the line. The substrate 12 for example, a spunbond or non-woven mesh is directed onto support rollers 15, 17 towards a treatment station including rotary spray heads 22 for application to a side 14 of the mesh 12. An optional treatment station (shown in FIG. phantom lines) which may include rotating spray heads 18 may also be used to apply the opposite side 23 of the substrate 12. The treatment station receives a supply of the treatment composition 30 from a reservoir (which does not appear). The treated substrat is then dried if necessary by traversing cylindrical containers of No. 25 dryers or other drying elements and then rolled into a roll or converted for the use for which they were manufactured. Alternative drying elements include ovens, air dryers, infrared dryers, air blowers and the like.

As mentioned above, a unique and surprising aspect of the present invention includes the ability of the treatment composition to be transferred from the substrat to the skin. It has been found that when a liquid enters the substrate, the treatment composition will dissolve in the liquid and then the mediated transfer of the liquid from the treatment composition to the skin will occur. In other words, the treatment composition that includes the beneficial agent for the health of the skin dissolves the substrate in the liquid, which is then deposited in the substantially continuous adhesive thin film of the beneficial agent for the health of the skin on the skin. The urine is an example of a liquid that can transfer the treatment composition from the substrate to the skin. As another example, the fluid generated by the body after abrasion or injury to the skin, can provide sufficient mediated transfer of the liquid from the skin. composition d treatment from the substrate, in this case, a bandage or adhered gauze. In general, when the humidity increases, the treatment composition is transferred to the skin to form a protective barrier.

An article shows 80, in this case a diaper, s shown in FIG 2. With reference to FIG 2, the majority of said personal care absorbent articles 80 include a liquid permeable topsheet or liner 82, a back sheet of outer barrier or cover 84 and an absorbent core 8 positioned between and contained by the upper sheet 82 and the rear leaf 84. The articles 80, such as the diapers can also some type of succession element 88 such as adhesive or fastening tape. mechanical hook or loop fasteners to keep the garment in place in the user. The substrate 12 can be used to form several portions of article but not limited to the top sheet or liner 82.

The following examples are offered as illustration, not as a form of limitation.

EXAMPLES The compositions of the present invention were formed by creating an emulsion of a beneficial agent for the salutation of the skin and water as a carrier liquid. Aqueous emulsions of zinc salt were prepared as the beneficial agent for the health of the skin, AHCOVEL, as the surfactant system, and, in some cases, SERICIN and CROSILK as the silk protein. The stable emulsions were diluted approximately 5% by weight of emulsion and applied to the surface of a non-woven fabric of polyolefin at 3 and 6% by weight by means of a saturation and compression immersion process as written with more detail below. The fabrics were tested to detect the rate of liquid admission, softness, skin transfer, skin protection, anti-inflammatory property, and the like, as described in more detail below.

Admission Speed of Liquids: This test identifies as liquid penetration EDANA 150.1-90 and measures the time it takes the volume of a known liquid (simulated urine) applied to the surface of a test sample woven in contact with a pad Underlying absorbent pair pass through the non-woven mesh. In general, a 50 ml test tube is placed in a universal holder with the tip inside a funnel. A standard 5-fold absorbent pad of specified filter paper (482% absorbency) is placed on an acrylic glass seat plate below the funnel, and a non-woven sample is placed on the surface of the absorbent material. An acrylic glass penetration plate 25m thick and weighing 500grm is placed on the sample with the cavity centered 5mm below the funnel. The pipette is filled with the liquid, keeping the funnel closed, and quantity of liquid (for example 5ml or lOml) passes into the funnel. The ml or lOml is allowed to run out when a stopwatch starts running and stops when the liquid has entered the pad and falls under a set of electrodes, and the elapsed time is recorded. The liquid used was Salino d Blood Bank, available from Blood Bank Saline, available from Stephens Scientific Co., Catalog Number 8504.

Softness Test: Although a specific softness test was not conducted, it was noted that each of the prepared samples had a "soft touch" and that it would be suitable for use in the articles described hereinabove.

Skin Transfer Test: According to the procedure suggested by Molecular Probes, Inc., Sericin was labeled with the fluorescent dye, Texas Red (TR), Eugene O (Red Texas protein labeling kit F-6112). A sericin emulsion of 4.5% by weight, 200 μl, was reacted with 100% solution of 5 mg / ml succinimide Red Texas and dimethyl sulfoxide for one hour. The protein marked in this way was separated by means of gel chromatography with centrifugation for three minutes at 1100 x g.

AHCOVEL emulsions containing an unlabeled d-TR mixture and unlabeled sericin were used to treat 0.6-os substrate and non-woven polypropylene mesh prepared as a diaper liner according to the procedure described. Fluorescent microscopy using a high-pressure Hg lamp with bandpass filters of excitation d emission of 595mm and 615nM, respectively, confirmed the presence of the labeled protein in the substrate. FIG 3 is a 200X optical microscopy (brightness and fluorescence field) of the substrate treated with the treatment composition according to the present invention. The substrate n treated did not show significant fluorescence, (not shown) By exposing the treated substrate to intense fluorescence water, characteristic of TR, a solution could be detected, suggesting the solubility of the labeled protein in the moisturizing medium. Sericin was removed from the substrat due to its solubility in water. FIG 4 is a 2OOX light microscope (fluorescent image) showing the mediated transfer of this liquid from the treatment composition from the treated substrate and dissolving in liquid.

The transfer of the labeled protein from the treated substrate to the skin was verified by the following procedure. A square centimeter of treated substrate secured the forearm of the palmar with adhesive tape. A majority of the substrate area was not covered with tape, which was placed only on the perimeter to secure the substrate to the arm. The substrate was subsequently moistened with 300uL of water After several minutes, the substrate was removed from the arm, and the Stratum Corneum previously covered by the material was fastened with Dsquame tape to remove the superficial layers of skin for fluorescent microscopic analysis. L microscopy at 100X and 200X clearly revealed intense fluorescence associated with the TR labeled protein, thereby confirming that the substrate transfer to the skin, mediated by definitive moisture. FIG% shows the thin, substantially continuous adhesive film of the silk protein that was applied by means of the present invention. The resulting protein coating morphology was consistent with a thin, adhesive, substantially continuous film of the protein, of sericin in the forearm corneositos. FIG, on the other hand, shows the variability of the application of the silk protein by means of a mechanical transfer described in the prior art.

The fabrics were tested for topical distribution of the zinc salt using skins excised in modified FRANZ diffusion cells. The amount of zinc that accumulates and penetrates the skin was determined over a period of 36 hours. The accumulation of zinc was determined at 1311 mg / g of dry weight of the skin, while the penetration was measured and resulted in 3. mg / cm2 / hr.

Skin Protection Test: The uniformity of the skin protective film as shown in FIG. 5 is indicative of good protective properties.

Anti-inflammatory property: The effect of the beneficial agent for the health of the skin was determined to inhibit the hydrolysis of a model protein substrate by urine and faecal extract. In addition, the ability of a beneficial agent for skin health was measured to reduce an inflammation-promoting response based on stool extract in EpiDerm ™. A silk protein applied to a material was also placed in the EpiDerm ™ sample, before after the application of the fecal irritant and they were evaluated to detect their ability to reduce a pro-inflammatory response of faecal extract. The release of a molecule of preinflammatory Interleukin-1 alpha, was compared to that of the contro that does not contain the beneficial agent for skin health.

Inhibition of the proteolytic activity of faecal extract It was shown that aqueous zinc salts inhibit a chemical reaction that contributes to the diaper rash. The proteolytic activity of a fecal extract was measured using fluorescently labeled caffeine. The inhibiting emulsions of zinc sulfate heptahydrate in water were prepared at 0-1 mM margins.

A stool extract sample of stool obtained from an infant was prepared on antibiotics (Sulfatrim) which had diaper rash. To prepare the extract, the stools were suspended in water and shaken vigorously. After vortexing, the sample was kept on ice before centrifuging at 15,000 times the force of gravity for 2 minutes. The float was filtered through 0.22 micron cellulose acetate filters and stored at -80 ° C until it was used. Trypsin was measured (molecular weight = 23,500 daltons, proteases known to contribute to the diaper rash, in the extract fecal concentration in a concentration of 5.850 picomoles / milliliter S measured the pancreatic elactase (molecular weight = 25,000 daltons, or suspect carrier, in the fecal extract in a -concentration d 83.6 picomoles / milliliter.The fecal extract (7.1 mg / ml in water it was diluted in water at 2 mg / ml.

Solutions of zinc sulfat heptahydrate (Aldrich Chemicals, Wl) solutions (20mL) with a molecular weight of 287.5 were added to the wells of a 96 white plate (Dynex Chantilly, VA) containing 100mL of a fecal extract and allowed to incubate during 15 minutes at room temperature. The reaction was initiated with the addition of 80mL of a solution of 12. mg / ml of a casein substrate labeled with fluorescent dye (Protease Assay Kit (E-6639), molecular probes Eugene, OR) in 20mM Tris-HCl, pH 8.0. The reaction of the fecal extract with the casein substrate penetrates the fluorescent dye of the substrate. The relative fluorescence units (RFU) s were collected using the Fluoroskan Asen system (Labsystems Incorporated, Needham Heights, MA) with emission excitation filters of 485 and 538nm, respectively. The data was collected every minute for 15 minutes and the speeds were calculated (RFU / min). Using the inhibited wells as a 100% protease activity, the percentage of the remainder of the fecal proteolytic activity was determined for each zinc inhibited concentration (inhibited rate / uninhibited velocity * 100).

The data show that zinc effectively inhibited the hydrolysis of casein by the fecal extract in a dose-dependent manner. A plot of the data for the fecal extract sample is shown in the FIG 7 graph showing the proteolytic activity of the fecal stratum was reduced as the concentration of zinc sulfate heptahydrate was increased. These data show that the aqueous zin emulsion has the ability to neutralize the proteases in the stool that have been implicated in inducing inflammation of the skin and the environment of the diaper (Anderson, pH., Bucher, AP, I., Lee PC Davis, JA, and Maibach, HI, Fecal enzymes: foot irritation in vivo Contact dermatitis 1994; 30, 152-158).

Inhibition of the infantile urine proteolytic activity It was shown that aqueous zinc salts inhibit a chemical reaction that contributes to the diaper rash. The proteolytic activity of infant urine was measured using fluorescently labeled casein. Zinc sulphate heptahydrate inhibitor solutions in water were prepared with margins of 0-50mM.

Two samples of infant urine were added (lOOmL) to the wells of a white plate 96 (Dynex) containing 80 mL of 12.5 mg / mL solution of a fluorescent dye-labeled casein substrate (EnzCheck Protease Assay Kit (E-6639)) in lOOmM of Tris-HCl, pH 8.0, and allowed to incubate for 60 minutes 37 degrees Celsius. The reaction started with the addition of 20mL of zinc sulfate heptahydrate in water, with zero-50mM margins. The reaction of the infant urine with the casein substrate penetrated the fluorescent tint of the substrate. RFUs were collected using the fuoroskan Ascent System with excitation and emission filters d 485 and 538mM, respectively, the data were collected at one minute for 60 minutes at 37 ° C and speeds (RFU / min) of 30-5 minutes were calculated for each zinc concentration. Using the uninhibited wells as a 100% protease activity, the percentage of the remaining orin proteolytic activity was determined for each concentration of the zinc inhibitor (inhibited velocity / uninhibited velocity * 100).

The data showed that zinc effectively inhibited the hydrolysis of casein by infant urine in a dose-dependent manner. A diagram of the data is shown in Figure 8, which is a graph showing how the proteolytic activity of the infant's urine was reduced as the concentration of zinc sulfate heptahydrate increased. These data show that the zinc solution. aqueous had the ability to neutralize the proteases in the infant's urine Inhibition of the Proteolytic Activity of Fecal Extract in Synthetic Skin It was shown that zin sulfate heptahydrate inhibits the reaction of faecal extract with synthetic skin. Synthetic foot, EpiDerm ™ 201 (MatTek Corporation, Ashland, MA contains keratinocytes that release interleukin-1 alpha (IL-alpha) when subjected to proteases in the fecal extract When IL-1 alpha is released, its expansion of the skin in the liquid below the EpiDerm ™ Samples of this fluid were taken and analyzed for the presence of IL-1 alpha Higher levels of IL-1 alpha were indicative of skin irritation.

Prior to the EpiDerm ™ application, the fecal extract (10.4mL) was preliminarily incubated for 3 minutes at room temperature with 250mM zinc heptahydrate d sulfate in water (2.6mL). Samples exclusively of agu and exclusively of fecal extract served as controls After the application of the samples to the EpiDerm ™, aliquots of 25mL of the underlying medium were removed in 8, 1 and 24 hours to test the presence of IL-1 alpha. The aliquots were added directly to a 1.5mL micro centrifug tube containing 225mL of 20mM Tris-HCL, pH 8.0, sterilized filtrate, pH 8.0, 1% BSA buffer and stored at -80 ° C. After all the samples were pooled, the levels of IL-1 alpha were quantified using the interleukin-1 alpha kit Quantikina from (R &D Systems, Minneapolis, MN) A diagram of the data is shown in FIG this graph shows that the addition of zinc sulfat heptahydrate (FE + zinc) reduced the amount of interleukin-1 alf released in the underlying medium relative to the application of substrate treated with fecal extract not inhibited (FE + water). A similar reduction was demonstrated in 8, 12 and 24 hours. The asterisc on the error bars in FIG 9 represent a confidence interval of 95% of the student's t-test.

Re-performing the same experiment with varying concentrations of zinc sulfate heptahydrate (0 25, 50, 125, and 250 mM) in the aliquot portion of 2.6 mL after the sample of 10.4 mL of fecal extract, showed that the heptahydrate of Zinc sulfate effectively inhibits the proteolytic activity of the faecal extract in a manner dependent on the dosage. A graph of the data, shown in Figure 10, shows that the proteolytic activity of fecal extract is reduced as the concentration of zinc heptahydrate d sulfate increases.

Effect of Zinc Salt on the pH of Urine and Fecal Extract The increase in the heptahydrate concentration of zinc sulfate reduced the pH of the urine and the fecal extract of the infant as shown below in Table 1. The p of the samples was measured using pH 4.5-10 test strips. (P-4536, Lot 067H1346, Sigma Chemical Co., St. Louis, MO). The p of the infant's urine samples were reduced 1.5-2. pH units and the pH of the fecal extract sample was reduced by one pH unit.

Table 1 - Effect of zinc concentration on pH Treatment composition The treatment compositions containing water, AHCOVEL, SERICIN, CROSILK, and zin sulfate monohydrate were prepared according to the following table 2. For comparison purposes, a control composition exclusively containing water and AHCOVEL was prepared.

Table 2 - Composition concentrations (% by weight) Although the data is not specifically shown for silk protein emulsions, without the aid of the surfactant, they were applied to a substrate. Because the protein is hydrophilic and the substrate is hydrophobic, the protein would not easily wet and saturate the substrate but would rather form a bubble in the upper part of the substrate.

Zinc Permeation of Skin Lotion The zinc permeation of aqueous lotions containing 1% zinc sulfate monohydrate in and through the skin of a human cadaver and EpiDerm ™ (epi-612, MatTe Corporation, Ashland, MA) was evaluated. The receiver compartment was filled with isotonic saline (0.9% NaCl) containing 0.1% formaldehyde preservative, maintained at 37 ° C + 0.5 ° C and continuously agitated at 600 rpm. No surfactants were added The skins (human cadaver skins with female abdomen neoplasm, and EpiDerm ™) were placed between the donor and recipient compartments in the Franz diffusion cells and fastened with staples. First the skins were allowed to equilibrate for one hour before experiment. Afterwards, any air bubble that will remain in the recipient's cells is removed. At that time, 500 mg was placed in the aqueous emulsion in each skin. All donor cells were occluded with Parafilm®. The samples from the recipient (1.5ml) were taken after 36 hours and frozen at -70 ° before analysis with coupled ion spectroscopy (ICP) to determine the flow of zinc through the skins.

After 36 hours the skins were removed from the cells and washed briefly in water. All skin samples were dried for 24 hours at 105 ° C. The dry skin samples were weighed and dissolved in nitric acid (68%) (EM NJ, USA), for 96 hours. The mixture was then filtered through a 0.22 micron filter (Millex ™ -GV, Millipore, Mass., USA) The emulsions were diluted 10 or 20 times before being subjected to ISP analysis to quantify the zinc content in the skin.

The zinc flow and the skin content were determined after 36 hours and are shown in table three. The results are expressed as average ± standard deviation. The number of samples is 3-4 per experiment. All the examples retained significant amounts of zinc. EpiDerm ™ was more permeable, retained more zinc compared to human cadaver skin.

Table 3: Percutaneous permeability parameters for zinc sulphate monohydrate.

Substrate Treaty Treated polypropylene yarns (base weight of approximately 0.5 ounces per square yard) were used as a substrate for the treatment compositions. The compositions were applied to the substrate by a batch treatment process with a low proportion of solids. An 8-inch x 12-inch (20.32 x 30.4-cm) sample of substrate was first immersed in a water treatment bath of known composition illustrated in the following table 4 Table 4 - Treatment Bath Concentration.

The saturated examples were then pressed between two rubber rollers in a laboratory drainer, type LW-1 No.LW-83A (Atlas Electric Devices, Chicago, IL), subsequently dried in an oven at 60 ° C for approximately 20 minutes or until constant weight is reached. The tightening pressure was adjusted to achieve 100% moisture collection (% WPU). The% WPU is calculated from the following equation: % WPU = [(Ww. Wd) / Wd] x 100 Where: Ww Wet weight of the tight fabric, Wd = Dry weight of the treated fabric.

Knowing the bath concentration and the% WP, the He addition can be calculated from the following equation Addition% = (% Bath Concentration) x (% WPU) + 100 • If, as in this example,% WPU = 100, then the percentage of addition will equal the percentage of Bath concentration. However, other combinations of% WP and% Bath Concentration can be used to achieve similar results. The percentage of final addition for each component of each sample is shown in the following table 5.

Table 5-Addition Percentage for each example of Table 4 The rate of liquid intake is determined for each of the examples in Table 5 as shown in the following Table 6, according to the test described above. As shown in the data, the liquid admission rates were not adversely affected by the addition of the treatment composition of the present invention, and the substrates, therefore, provide adequate liquid handling properties. Table 6 - Liquid Admission Time (seconds) Example Admission time (seconds) # Traumatism Traumatism Traumatism Traumatism Trauma or 1 2 3 4 5 2 2.82 2.83 3.05 3.21 3.15 3 2.45 2.43 2.54 2.47 2.65 5 2.38 2.41 2.43 2.35 2.55 6 2.63 2.69 2.60 2.72 2.70 7 2.51 2.72 2.43 2.32 2.38 8 2.44 2.56 2.37 2.38 2.42 Treated Zinc Permeability of the Skin The permeability of the zinc from the treated non-woven yarn of Examples 7 and 8 of Table 5 in and through the foot of the human cadaver was evaluated. The modified FRANZ diffusion cells (Permegear Inc. Riegelsville, PA) were used for the in vi tro between (diffusion areas of 0.64 cm2, volume d compartment or 5.1 ml receiver.) The receptor compartment was filled with isotonic saline (0.9%). NaCl) containing 0.1% d ^ formaldehyde preservative, maintained at 37 ° C ± 0.5 ° C, and shaken continuously at 600 rpm. No surfactants were added.

The skins (skins of human corpse with neoplasm, female abdomen) were installed between the compartments of the donor and the recipient in the diffusion cell.

FRANZ and they were clamped. First it was allowed that the skins will reach a balance for an hour or before experiment. Then any residual air bubbles in the receiver cells were removed. At that time, a circle was cut from the non-woven mesh and fastened to the top of the foot in each cell. Distilled water (500ml) was placed in the upper part of each material and the donor cell was occluded.

Parafilm®. The samples from the receptor (1.5mml) were taken after 36 hours and were frozen at -70 ° C before the analysis of coupled ion spectroscopy (ISP) to determine the zinc flow through the skins.

After 36 hours, the skins were removed from the cells and previously washed in water. All skin samples were dried for 24 hours at 105 ° C. The dry foot samples were weighed and dissolved in nitric acid (68%) (EM, NJ USA) for 96 hours. Then the mixture was filtered through a 0.22 micron filter (Millex ™ -GV, Millipore, Mass., USA). The emulsions were diluted 10 or 20 times before being subjected to ISP analysis for the quantification of zinc and skin content. .

The zinc flow and the zinc content determined after 36 hours and is shown in table 7. The results are expressed as average deviation + standard deviation. The number of examples analyzed is 3-4 per experiment. All the examples retained a significant amount of zinc.

Table 7: Percutaneous Permeability Parameters for Zinc Sulphate Monohydrate.

Inhibition of the proteolytic activity of Fecal extract The treated yarn materials were tested to evaluate their ability to inhibit the reaction of fecal extract with synthetic skin. The fecal extract is prepared from the stool obtained from an infant with antibiotics (Sulfatrim) who had a diaper rash. To prepare the extract, the extracts were suspended in water and shaken vigorously. After shaking, the samples were kept on ice before reviewing the centrifugation at 15,000 times the gravity strength for 20 minutes. The float was filtered through 0.22 micron cellulose acetate filters and stored at -80 ° C until it was used. Pepsin (molecular weight equal to 23,500 daltons) a protease known to contribute to diaper rash, s measured in the fecal extract at a concentration of 5,850 picomole / milliliters. Pancreatic elastase (molecular weight equal to 2 daltons, a suspect contributor, was measured in the fecal extract at a concentration of 83.6 picomoles / milliliters.) Synthetic skin, EpiDerm ™ 201 (MatTe Corporation, Ashland, MA) contains keratinocytes that release interleukin-1 alpha (IL-1 alpha) when subjected to proteases such as trypsin and pancreatic elastase. When s releases IL-1 alpha, it is diluted from the skin in the fluid under the EpiDerm ™. Fluid samples were taken and analyzed to verify the presence of IL-1 alpha. High levels of IL-alpha are indicative of great skin irritation.

. To perform the experiment, lOmL d water was applied to the surface of the synthetic skin. The treated yarn materials were cut into approximately 0.9 cm discs that were placed on top of the water in EpiDerm ™. After D about 2hrs of incubation at approximately 30 ° C, the discs were removed and the EpiDerm ™ was attacked with 15mL of attack liquid where each of the disks and treated cloth had been. A second spinning disc treated was then placed on the top of the attack liquid to simulate the environment of the diaper. After 11 hours at 37 ° C, an aliquot of the underlying liquid bathing the EpiDerm ™ was removed and the amount of IL-1 alpha was quantified using the interleukin-1 alpha quantikin kit (R &D Systems Minneapolis , MN).

Four treatments were carried out using the examples given in table 5 and two attack liquids (fecal extract and water) as shown in table 8.

Table 8: Treatment of EpiDerm ™ The results of the experiments in the table are shown below in Table 9. The application of the materials treated with Crosilk and Zinc (code K) to the EpiDerm reduced the amount of interleukin-1 alpha released in the underlying medi relative to the application of materials treated only with Ahcovel (Code I).

Table 9: IL-1 alpha Released (picograms / milliliter) Although several Patents and other reference materials have been included herein by reference, in the extent to which any inconsistency between the included material and that of the present written specification is found, the written specification prevails. Furthermore, although the present invention has been described in connection with certain preferred embodiments, it is understood that the material subject matter covered by the present invention is not limited to said specific embodiments. On the contrary, it is the intention of the asunt of the intention to include all the alternative modifications and equivalents that may be included within the spirit and scope of the following claims.

Claims (29)

1. A combination of treatment for imparting a liquid mediated transfer medium to a substrate, said combination comprises a surfactant and a beneficial agent for skin health; the surfactant includes a compound selected from the group comprising hydrogenated fatty acids ethoxylated monosaccharides, monosaccharide derivatives, polysaccharides derived from polysaccharides and combinations thereof.

2. The combination of treatment, as claimed in clause 1, characterized in that the beneficial agent for skin health comprises zinc salt aqueous zinc sulfate monohydrate.

3. The combination of the treatment, as claimed in clause 2, characterized in that the surfactant and the beneficial agent for skin health are combined in an aqueous emulsion to form a treatment composition.

4. The treatment combination, as claimed in clause 2, characterized in that the surfactant and the zinc salt form a treatment composition and are present in a weight ratio of about 0.01-25 by weight of zinc salt for about 75-99.99% in surfactant weight.

5. The treatment combination, as claimed in clause 4, characterized in that the emulsion further comprises 0.1 to 40% by weight of total solids.

6. The treatment composition, as claimed in clause 5, characterized in that it also comprises a protein.

7. The treatment composition, as claimed in clause 6, characterized in that the protein also comprises a silk protein.

8. A substrate treated with a treatment combination, the treatment combination comprises either surfactant and a beneficial agent for skin health; the surfactant includes a compound selected from the group comprising hydrogenated ethoxylated monosaccharide fatty oils, monosaccharide derivatives, polysaccharides derived from polysaccharides and combinations thereof. wherein the surfactant is a liquid mediated transfer medium for transfer of the beneficial agent for the skin health of the substrate to a user.

9. The substrate treated, as claimed in clause 8, characterized in that the beneficial agent for skin health also comprises zinc salt or zinc sulfate heptahydrate.

10. The substrate treated, as claimed in clause 9, characterized in that the substrate is selected d woven fabrics, knitted fabrics, non-woven meshes, foams, film materials and paper materials.

11. The substrate treated, as claimed in clause 10, characterized in that the substrate comprises a non-woven mesh.

12. The treated substrate, as claimed in clause 11, characterized in that the mesh is non-woven and hydrophilic.

13. The treated substrate, as claimed in clause 12, characterized in that the non-woven mesh comprises a spun mesh, a molten mesh, a shaped mesh or an agglomerated carded mesh.

14. The treated substrate, as claimed in clause 13, characterized in that the substrate comprises a multilayer sheet.

15. The treated substrate, as claimed in clause 11, characterized in that the combination d treatment further comprises a protein.

16. The combination of treatment, as claimed in clause 15, characterized in that the protein also comprises a silk protein.

17. The treated substrate, as claimed in clause 16, characterized in that the combination is applied at a level of approximately 0.1-1.5% by weight of surfactant relative to the base weight of the substrate.

18. The substrate treated, as claimed in clause 17, characterized in that the combination is applied at a level of approximately 0.1-1.0% by weight of the surfactant relative to the base weight of the substrate.

19. The substrate treated, as claimed in clause 18, characterized in that the combination is applied at a level of approximately 0.1-0.5% by weight of surfactant relative to the basis weight of the substrate.

20. A personal care product comprising the treated substrate of clause 11.

21. The personal care product, as claimed in clause 20, characterized in that the personal care product is selected from a diaper, an underpants trainer an absorbent underpants, an incontinence product for adults a sanitary napkin, a hygiene product feminine, a vend and gauze for wounds.

22. The personal care product, as claimed in clause 21, characterized in that the agent beneficial for the health of the skin lowers the pH of the ambient of the personal care product.

23. The substrate treated, as claimed in clause 11, characterized in that the rate of admission of a liquid from the substrate is not adversely affected by adding the treatment combination.

24. A method for transferring a thin, adhesive, substantially continuous thin film of beneficial agent for skin health to the skin comprising: a) provide a substrate; b) applying a treatment composition to a substrate, the composition comprising a surfactant and a beneficial agent for the health of the skin in combination; The surfactant includes a compound selected from the group consisting of hydrogenated ethoxylated monosaccharide fatty oils, monosaccharide derivatives, polysaccharides derived from polysaccharides and combinations thereof, c) attacking the substrate with an aqueous-based liquid by means of which the composition of the treatment is dissolved in the liquid, and d) transferring the substrate treatment composition to the skin, thereby forming a thin adhesive film, substantially continuous on the skin.

25. The method, as claimed in clause 24, characterized in that the substrate is a hydrophilic non-woven mesh.

26. The method, as claimed in clause 25, characterized in that the substrate comprises a personal care product.

27. The method, as claimed in the clause 25, characterized in that the beneficial agent for skin health also comprises aqueous zinc salt or aqueous zinc sulfate heptahydrate.

28. The method, as claimed in clause 27, characterized in that it also comprises the addition of a protein to the substrate.

29. The method, as claimed in clause 28, characterized in that the protein further comprises a silk protein.